ABSTRACT
Objective@#To evaluate the effectiveness of family interventions among children with allergic rhinitis receiving immunotherapy, so as to provide insights into improvements of allergic rhinitis treatment.@*Methods@#A total of 80 children with allergic rhinitis admitted to The First People's Hospital of Linping District from July 2018 to July 2021 were enrolled and randomly assigned into the control and intervention groups, of 40 participants in each group, and all children underwent immunotherapy. Children in the control group received routine interventions, while participants in the intervention group were given family interventions for 3 months, including health education, psychological counseling, and periodical follow-up. Parental awareness of allergic rhinitis was investigated using self-designed questionnaires, and the compliance to immunotherapy was evaluated. The clinical symptoms were evaluated using the symptom scores and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and the prognosis was evaluated using the Sino-Nasal Outcome Test-20 (SNOT-20).@*Results@#There were no significant differences between the intervention and control groups in terms of gender, age, course of disease or disease severity (P>0.05). The scores for parental awareness of etiology [(9.56±0.25) vs. (7.45±0.85)], inducement factor [(8.84±0.62) vs. (6.76±1.36)], medication management [(9.56±0.25) vs. (7.97±0.85)] and daily life management of allergic rhinitis [(9.14±0.55) vs. (8.14±0.46)] were significantly higher in the intervention group than in the control group (P<0.05). The proportion of participants' compliance to immunotherapy was significantly higher in the intervention group than in the control group (92.50% vs. 75.00%, P<0.05). The scores for clinical symptoms [(3.12±0.94) vs. (3.96±1.23)], RQLQ score [(3.31±0.87) vs. (3.87±1.02)] and the SNOT-20 scores for nasal symptoms [(6.54±2.14) vs. (8.22±2.45)], sleep disorders [(4.11±0.58) vs. (5.24±1.03)], associated symptoms [(5.29±1.52) vs. (6.34±2.01)] and emotional consequences [(7.52±1.85) vs. (9.19±2.69)] were significantly lower in the intervention group than in the control group post-interventions (P<0.05).@*Conclusion@#Family interventions are effective to improve the compliance to immunotherapy, clinical symptoms, prognosis and quality of life among children with allergic rhinitis
ABSTRACT
Objective To observe the clinical effect of bevacizumab and temozolomide combined with concurrent radiotherapy for elderly patients with malignant brain glioma after the surgery . Methods A total of 55 patients in department of neurosurgery of Lanzhou Military Region General Hospital from January 2013 to December 2015 were enrolled. The patients were divided into control group and observation group. The 25 cases in the control group received radiotherapy and temozolomide. The 30 cases in the observation group received bevacizumab and temozolomide combined with concurrent radiotherapy. After treatment for 6 and 12 months, the clinical effects and adverse reactions of the two groups were compared byχ2 test, and the survival was compared by Log-rank test . Results Patients in the treatment group were followed up for 6 months after chemoradiotherapy, the response rate (RR) was 80 ％ (24/30), the disease control rate (DCR) was 97 ％ (29/30). The RR and DCR in the control group were 68 ％ (17/25) and 84 ％(21/25). There were significant differences between the two groups (χ2 values were 3.742 and 8.000, both P<0.05). After 12 months of follow-up, the RR and DCR in the treatment group were 40 ％ (12/30) and 80 ％(24/30), the control group were 16％(4/25) and 56％(14/25). There were significant differences between the two groups (χ2 values were 3.547 and 1.983, both P< 0.05). The adverse effect rates had no significant difference between the two groups (all P> 0.05). The 2-year survival rates in the treatment group and control group were 28.2 ％ and 11.0 ％, the difference was statistically significant (χ 2 = 4.512, P = 0.034). Conclusions Temozolomide and bevacizumab combined with concurrent radiotherapy in treatment of malignant glioma is superior to temozolomide combined with radiotherapy, and bevacizumab is safe and has few side effects. It is a preferred treatment and is worthy of clinical promotion.
ABSTRACT
Objective To preliminarily explore the effects and brain protective mechanism of intermittent hypoxia preconditioning ( IHP) on rats with seizures induced by lithium-pilocarpine ( Li-pilo) .Methods A total of 96 8-week old male Sprague Dawley rats ( clean grade ) were randomly divided into control group , seizure group and four IHP-seizure groups.The animal model of epilepsy was established by intraperitoneal injection of Li-pilo in the seizure group and four IHP-seizure groups (Li-pilo was injected at 1, 3, 7, or 14 days after a 5-day regimen of IHP).Subsequent seizure behavior , the latency period and percentage of generalized seizures were quantitatively evaluated for 240 min and the cognitive function was tested by Morris water maze task , and followed by the detection of hippocampus neuron apoptosis and related protein (BCL-2, Bax, and cleaved-caspase-3) by TUNEL labeling and Western blot, respectively.Results The induced seizure peaked on an average between 50-150 min after Li-pilo administration , scored using a modified Racine scale.The average scores of modified Racine scale in the IHP-3d seizure group was significantly lower than that in the other groups.The latency period and percentage of generalized seizures in the IHP-3d seizure group rats were significantly different from the parameters in the seizure group rats (P0.05).Conclusions The results indicate that IHP treatment may help to decrease the susceptibility to epilepsy by reducing abnormal apoptosis , and has a brain protective effect on the seizure rats .